Tachyarrhythmias are disorders of heart rhythm which may present with a tachycardia i.e. a heart rate >100 bpm.
This article provides an overview of tachyarrhythmias in general and goes on to cover the most common tachyarrhythmias in more detail. The acute management of tachyarrhythmias, in an emergency setting, will be covered in the 'Acute' section of the fastbleep website.
Tachyarrhythmias are clinically important as they can precipitate cardiac arrest, cardiac failure, thromboembolic disease and syncopal events. As such, they crop up time and time again in exam papers and on the wards.
Tachyarrhythmias are classified based on whether they have broad or narrow QRS complexes on the ECG. Broad is defined as >0.12s (or more than 3 small squares on the standard ECG). Narrow is equal to or less than 0.12s. Broad QRS complexes are slower ventricular depolarisations that arise from the ventricles. Narrow complexes are ventricular depolarisations initiated from above the ventricles (known as supraventricular). One important exception is when there is a supraventricular depolarisation conducted through a diseased AV node. This will produce wide QRS complexes despite the rhythm being supraventricular in origin.
Wolff–Parkinson–White syndrome (WPW) is one of several disorders of the conduction system of the heart that are commonly referred to as pre-excitation syndromes. WPW is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals traveling down this abnormal pathway (known as the bundle of Kent) may stimulate the ventricles to contract prematurely, resulting in a unique type of supra-ventricular tachycardia referred to as an atrio-ventricular reciprocating tachycardia.
AV nodal reentrant tachycardia (AVNRT), or atrioventricular nodal reentrant tachycardia, is a type of tachycardia (fast rhythm) of the heart. It is a type of supraventricular tachycardia (SVT), meaning that it originates from a location within the heart above the bundle of His. AV nodal reentrant tachycardia is the most common regular supraventricular tachycardia. It is more common in women than men (approximately 75% of cases occur in females). The main symptom is palpitations. Treatment may be with specific physical maneuvers, medication, or, rarely, synchronized cardioversion. Frequent attacks may require radiofrequency ablation, in which the abnormally conducting tissue in the heart is destroyed.
AVNRT occurs when a reentry circuit forms within or just next to the atrioventricular node. The circuit usually involves two anatomical pathways: the fast pathway and the slow pathway, which are both in the right atrium. The slow pathway (which is usually targeted for ablation) is located inferior and slightly posterior to the AV node, often following the anterior margin of the coronary sinus. The fast pathway is usually located just superior and posterior to the AV node. These pathways are formed from tissue that behaves very much like the AV node, and some authors regard them as part of the AV node.
The fast and slow pathways should not be confused with the accessory pathways that give rise to Wolff-Parkinson-White syndrome (WPW syndrome) or atrioventricular reciprocating tachycardia (AVRT). In AVNRT, the fast and slow pathways are located within the right atrium close to or within the AV node and exhibit electrophysiologic properties similar to AV nodal tissue. Accessory pathways that give rise to WPW syndrome and AVRT are located in the atrioventricular valvular rings. They provide a direct connection between the atria and ventricles, and have electrophysiologic properties similar to ventricular myocardium.
Wolff–Parkinson–White syndrome (WPW) is one of several disorders of the conduction system of the heart that are commonly referred to as pre-excitation syndromes. WPW is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals traveling down this abnormal pathway (known as the bundle of Kent) may stimulate the ventricles to contract prematurely, resulting in a unique type of supra-ventricular tachycardia referred to as an atrio-ventricular reciprocating tachycardia.
AV nodal reentrant tachycardia (AVNRT), or atrioventricular nodal reentrant tachycardia, is a type of tachycardia (fast rhythm) of the heart. It is a type of supraventricular tachycardia (SVT), meaning that it originates from a location within the heart above the bundle of His. AV nodal reentrant tachycardia is the most common regular supraventricular tachycardia. It is more common in women than men (approximately 75% of cases occur in females). The main symptom is palpitations. Treatment may be with specific physical maneuvers, medication, or, rarely, synchronized cardioversion. Frequent attacks may require radiofrequency ablation, in which the abnormally conducting tissue in the heart is destroyed.
AVNRT occurs when a reentry circuit forms within or just next to the atrioventricular node. The circuit usually involves two anatomical pathways: the fast pathway and the slow pathway, which are both in the right atrium. The slow pathway (which is usually targeted for ablation) is located inferior and slightly posterior to the AV node, often following the anterior margin of the coronary sinus. The fast pathway is usually located just superior and posterior to the AV node. These pathways are formed from tissue that behaves very much like the AV node, and some authors regard them as part of the AV node.
The fast and slow pathways should not be confused with the accessory pathways that give rise to Wolff-Parkinson-White syndrome (WPW syndrome) or atrioventricular reciprocating tachycardia (AVRT). In AVNRT, the fast and slow pathways are located within the right atrium close to or within the AV node and exhibit electrophysiologic properties similar to AV nodal tissue. Accessory pathways that give rise to WPW syndrome and AVRT are located in the atrioventricular valvular rings. They provide a direct connection between the atria and ventricles, and have electrophysiologic properties similar to ventricular myocardium.
Wolff–Parkinson–White syndrome (WPW) is one of several disorders of the conduction system of the heart that are commonly referred to as pre-excitation syndromes. WPW is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals travelling down this abnormal pathway (known as the bundle of Kent) may stimulate the ventricles to contract prematurely, resulting in a unique type of supraventricular tachycardia referred to as an atrioventricular reciprocating tachycardia.The incidence of WPW is between 0.1% and 0.3% in the general population.Sudden cardiac death in people with WPW is rare (incidence of less than 0.6%), and is usually caused by the propagation of an atrial tachydysrhythmia (rapid and abnormal heart rate) to the ventricles by the abnormal accessory pathway.
A 45 years old lady presented with generalized weakness and palpitations. She is a diagnosed case of chronic renal failure with Diabetes mellitus and Hypertension. Her serum K+ level is 6.8 meq/L. She had the following ECG.
Case; A 54 years old gentleman complained of chest discomfort on exertion for the last 5 months. He is smoker for 10 years, diabetic for 5 years and hypertensive for 3 years. He had the following ECG.
Case: A 25 years old gentleman presented with chest pain and fever .He was normotensive, non-smoker and non-diabetic. His pulse 128b/min and BP-130/80 mm Hg. Troponin I was normal.
Case: A 58 years old gentleman complained of severe central chest pain with excessive sweating 5 days back. He is smoker for 7 years, diabetic for 5 years and hypertensive for 4 years. His BP-90/70 mm Hg. He had the following ECG.
A comprehensive approach to Atrial Fibrillation. Everything you need to know about Atrial fibrillation. Including recent 2014 AHA guidelines of management.
Wolff–Parkinson–White syndrome (WPW) is one of several disorders of the conduction system of the heart that are commonly referred to as pre-excitation syndromes. WPW is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals travelling down this abnormal pathway (known as the bundle of Kent) may stimulate the ventricles to contract prematurely, resulting in a unique type of supraventricular tachycardia referred to as an atrioventricular reciprocating tachycardia.The incidence of WPW is between 0.1% and 0.3% in the general population.Sudden cardiac death in people with WPW is rare (incidence of less than 0.6%), and is usually caused by the propagation of an atrial tachydysrhythmia (rapid and abnormal heart rate) to the ventricles by the abnormal accessory pathway.
A 45 years old lady presented with generalized weakness and palpitations. She is a diagnosed case of chronic renal failure with Diabetes mellitus and Hypertension. Her serum K+ level is 6.8 meq/L. She had the following ECG.
Case; A 54 years old gentleman complained of chest discomfort on exertion for the last 5 months. He is smoker for 10 years, diabetic for 5 years and hypertensive for 3 years. He had the following ECG.
Case: A 25 years old gentleman presented with chest pain and fever .He was normotensive, non-smoker and non-diabetic. His pulse 128b/min and BP-130/80 mm Hg. Troponin I was normal.
Case: A 58 years old gentleman complained of severe central chest pain with excessive sweating 5 days back. He is smoker for 7 years, diabetic for 5 years and hypertensive for 4 years. His BP-90/70 mm Hg. He had the following ECG.
A comprehensive approach to Atrial Fibrillation. Everything you need to know about Atrial fibrillation. Including recent 2014 AHA guidelines of management.
a clinical syndrome that results from inadequate tissue perfusion.
Hypovolemic shock - Blood or fluid loss, both leading to a decreased circulating blood volume, diastolic filling pressure, and volume.
Cardiogenic shock - due to cardiac pump failure related to loss of myocardial contractility/functional myocardium or structural/mechanical failure of the cardiac anatomy and characterized by elevations of diastolic filling pressures and volumes
Extra-cardiac/obstructive shock - due to obstruction to flow in the cardiovascular circuit and characterized by either impairment of diastolic filling or excessive afterload
Distributive shock - caused by loss of vasomotor control resulting in arteriolar/venular dilatation leading to a decrease in preload, with decreased, normal, or elevated cardiac output, depending on the presence of myocardial depression.
The primary treatment goals for patients with hepatitis B (HBV) infection are to prevent progression of the disease, particularly to cirrhosis, liver failure, and hepatocellular carcinoma (HCC).
Risk factors for progression of chronic HBV include the following :
Persistently elevated levels of HBV DNA and, in some patients, alanine aminotransferase (ALT), as well as the presence of core and precore mutations seen most commonly in HBV genotype C and D infections
Male sex
Older age
Family history of HCC
Alcohol use
Elevated alpha-fetoprotein (AFP)
Coinfection with hepatitis D (delta) virus (HDV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
A synergistic approach of suppressing viral load and boosting the patient’s immune response with immunotherapeutic interventions is needed for the best prognosis. The prevention of HCC often includes the use of antiviral treatment using pegylated interferon (PEG-IFN) or nucleos(t)ide analogues.
HBV infection can be self-limited or chronic. No specific therapy is available for persons with acute hepatitis B; treatment is supportive.
Patients with acute hepatitis C virus (HCV) infection appear to have an excellent chance of responding to 6 months of standard therapy with interferon (IFN). Because spontaneous resolution is common, no definitive timing of therapy initiation can be recommended; however, waiting 2-4 months after the onset of illness seems reasonable.
Treatment for chronic HCV is based on guidelines from the Infectious Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases (AASLD), in collaboration with the International Antiviral Society-USA (IAS-USA). These guidelines are constantly being updated. For more information, see HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
The guidelines propose that because all patients cannot receive treatment immediately upon the approval of new agents, priority should be given to those with the most urgent need.
The recommendations include the following :
Patients with advanced fibrosis, those with compensated cirrhosis, liver transplant recipients, and those with severe extraheptic hepatitis are to be given the highest priority for treatment
Based on available resources, patients at high risk for liver-related complications and severe extrahepatic hepatitis C complications should be given high priority for treatment
Treatment decisions should balance the anticipated reduction in transmission versus the likelihood of reinfection in patients whose risk of HCV transmission is high and in whom HCV treatment may result in a reduction in transmission (eg, men who have high-risk sex with men, active injection drug users, incarcerated persons, and those on hemodialysis)
Interstitial Lung Diseases [ILD] Approach to ManagementArun Vasireddy
Diffuse (interstitial) lung disease includes a wide variety of relatively uncommon conditions presenting with characteristic clusters of clinical features and marked by an immune response. There are over 200 specific diffuse lung diseases, many of unknown etiology. The combined incidence is 50 per 100,000, or 1 in 2000 people. Because these conditions cause aberrant lung function, morbidity and mortality due to lung injury and fibrosis are not uncommon. Both environmental and genetic factors are believed to contribute to the development of diffuse lung disease. Antigen processing and presentation are important in the development of the immune response seen in the disease, and it is thought that the likely candidate genes predisposing patients to this category of disease are those of the major histocompatibility complex. Genes that affect the immune, inflammatory, and fibrotic processes may also influence who develops the disease. If we can identify the genes that cause diseases characterized by lung injury and fibrosis, we can eventually develop genetic interventional approaches to treatment.
Amniotic Fluid Embolism [AFE] Approach to ManagementArun Vasireddy
Amniotic fluid embolism (AFE) is a life threatening obstetric emergency characterized by sudden cardiorespiratory collapse and disseminated intravascular coagulation.
Steiner and Luschbaugh first described AFE in 1941, after they found fetal debris in the pulmonary circulation of women who died during labor. Data from the National Amniotic Fluid Embolus Registry (USA) suggest that the process is more similar to anaphylaxis than to embolism, and the term anaphylactoid syndrome of pregnancy has been suggested because fetal tissue or amniotic fluid components are not universally found in women who present with signs and symptoms attributable to AFE.
The diagnosis of AFE has traditionally been made at autopsy when fetal squamous cells are found in the maternal pulmonary circulation; however, fetal squamous cells are commonly found in the circulation of laboring patients who do not develop the syndrome. The diagnosis is essentially one of exclusion based on clinical presentation. Other causes of hemodynamic instability should not be neglected.
Approach to Management of Upper Gastrointestinal (GI) BleedingArun Vasireddy
Upper gastrointestinal bleeding is gastrointestinal bleeding in the upper gastrointestinal tract, commonly defined as bleeding arising from the esophagus, stomach, or duodenum. Blood may be observed in vomit (hematemesis) or in altered form in the stool (melena). Depending on the severity of the blood loss, there may be symptoms of insufficient circulating blood volume and shock. As a result, upper gastrointestinal bleeding is considered a medical emergency and typically requires hospital care for urgent diagnosis and treatment. Upper gastrointestinal bleeding can be caused by peptic ulcers, gastric erosions, esophageal varices, and some rarer causes such as gastric cancer.
The initial assessment includes measurement of the blood pressure and heart rate, as well as blood tests to determine hemoglobin concentration. In significant bleeding, fluid replacement is often required, as well as blood transfusion, before the source of bleeding can be determined by endoscopy of the upper digestive tract with an esophagogastroduodenoscopy. Depending on the source, endoscopic therapy can be applied to reduce rebleeding risk. Specific medical treatments (such as proton pump inhibitors for peptic ulcer disease) or procedures (such as TIPS for variceal hemorrhage) may be used. Recurrent or refractory bleeding may lead to need for surgery, although this has become uncommon as a result of improved endoscopic and medical treatment.
Scrub typhus is a mite-borne disease caused by Orientia tsutsugamushi (formerly Rickettsia tsutsugamushi). Symptoms are fever, a primary lesion, a macular rash, and lymphadenopathy. (See also Overview of Rickettsial and Related Infections.) Scrub typhus is related to rickettsial diseases.
Pulmonary edema is often caused by congestive heart failure. When the heart is not able to pump efficiently, blood can back up into the veins that take blood through the lungs. As the pressure in these blood vessels increases, fluid is pushed into the air spaces (alveoli) in the lungs.
The jugular venous pressure (JVP, sometimes referred to as jugular venous pulse) is the indirectly observed pressure over the venous system via visualization of the internal jugular vein. It can be useful in the differentiation of different forms of heart and lung disease.
A treadmill exercise stress test is used to determine the effects of exercise on the heart. Exercise allows doctors to detect abnormal heart rhythms (arrhythmias) and diagnose the presence or absence of coronary artery disease.
This test involves walking in place on a treadmill while monitoring the electrical activity of your heart. Throughout the test, the speed and incline of the treadmill increase. The results show how well your heart responds to the stress of different levels of exercise.
Description
A technologist will explain the test to you, take a brief medical history, and answer any questions you may have. Your blood pressure, heart rate, and electrocardiogram (ECG) will be monitored before, during, and after the test.
You will be asked to sign a consent form. This form is required before the test can proceed.
You will be asked to remove all upper body clothing, and to put on a gown with the opening to the front.
Adhesive electrodes will be put onto your chest to capture an ECG. The sites where the electrodes are placed will be cleaned with alcohol and shaved if necessary. A mild abrasion may also be used to ensure a good quality ECG recording.
Your resting blood pressure, heart rate, and ECG will be recorded.
You will be asked to walk on a treadmill. The walk starts off slowly, then the speed and incline increases at set times. It is very important that you walk as long as possible because the test is effort-dependent.
You will be monitored throughout the test. If a problem occurs, the technologist will stop the test right away. It is very important for you to tell the technologist if you experience any symptoms, such as chest pain, dizziness, unusual shortness of breath, or extreme fatigue.
Following the test, you will be asked to lie down. Your blood pressure, heart rate, and ECG will be monitored for three to five minutes after exercise.
The data will be reviewed by a cardiologist after the test is completed. A report will be sent to the doctor(s) involved in your care.
A mosquito-borne viral disease occurring in tropical and subtropical areas.
Spreads by animals or insects
Requires a medical diagnosis
Lab tests or imaging often required
Short-term: resolves within days to weeks
Those who become infected with the virus a second time are at a significantly greater risk of developing severe disease.
Symptoms include high fever, headache, rash and muscle and joint pain. In severe cases there is serious bleeding and shock, which can be life threatening.
Treatment includes fluids and pain relievers. Severe cases require hospital care.
Adrenal gland & Cushing's Disease - Seminar August 2015Arun Vasireddy
A condition that occurs from exposure to high cortisol levels for a long time.
Fewer than 1 million cases per year (India)
Treatable by a medical professional
Requires a medical diagnosis
Lab tests or imaging always required
Chronic: can last for years or be lifelong
The most common cause is the use of steroid drugs, but it can also occur from overproduction of cortisol by the adrenal glands.
Signs are a fatty hump between the shoulders, a rounded face and pink or purple stretch marks.
Treatment options include reducing steroid use, surgery, radiation and medication.
Osteoporosis is a progressive systemic skeletal disease characterized by low bone mass and microarchitecture deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
2. Descriptive Physiology
• The normal cardiac impulse is generated by pacemaker cells
in the SA node situated at the junction of the right atrium and
the superior vena cava .
• This impulse is transmitted slowly through nodal tissue to the
anatomically complex atria, where it is conducted more
rapidly to the AV node, inscribing the P wave.
• The time needed for activation of the atria and the AVN delay
is represented as the PR interval.
• The AVN is the only electrical connection between the atria
and the ventricles in the normal heart.
• The electrical impulse emerges from the AVN and is
transmitted to the His-Purkinje system, facilitating activation
of ventricular muscle.
3. Descriptive Physiology
• the ventricles are activated rapidly through the Purkinje
network, inscribing the QRS complex.
• Recovery of electrical excitability occurs more slowly and is
governed by the time of activation and duration of
regional action potentials.
• The relative brevity of epicardial action potentials in the
ventricle results in repolarization that occurs first on the
epicardial surface and then proceeds to the endocardium,
which inscribes a T wave normally of the same polarity as
the QRS complex.
• The duration of ventricular activation and recovery is
determined by the action potential duration and is
represented on the body surface ECG by the QT interval.
4. • Cardiac myocytes exhibit a characteristically long action potential (200–
400 ms) compared with neurons and skeletal muscle cells (1–5 ms).
• The action potential profile is sculpted by the orchestrated activity of
multiple distinctive time- and voltage-dependent ionic currents.
• The currents are carried by transmembrane proteins that passively
conduct ions down their electrochemical gradients through selective pores
(ion channels), actively transport ions against their electrochemical
gradient (pumps, transporters), or electrogenically exchange ionic species
(exchangers).
• Action potentials in the heart are regionally distinct. The regional
variability in cardiac action potentials is a result of differences in the
number and types of ion channel proteins expressed by different cell types
in the heart.
• Further, unique sets of ionic currents are active in pacemaking and muscle
cells, and the relative contributions of these currents may vary in the same
cell type in different regions of the heart
5. MECHANISMS OF TACHYARRHYTHMIAS
• Cardiac arrhythmias result from abnormalities of electrical impulse
generation, conduction, or both.
• Classified according to mechanisms involved:
Alterations in Impulse Initiation: Enhanced Automaticity
Afterdepolarizations and Triggered Automaticity
Abnormal Impulse Conduction: Reentry
6. Automaticity
• Heart cells other than those of the SA node depolarize
faster than SA node cells, and take control as the cardiac
pacemaker.
(spontaneous depolarization of atrial, junctional, or ventricular
pacemakers)
• Factors that enhance automaticity include:
SANS, PANS, CO2, O2, H+, stretch, hypokalemia and
hypocalcaemia.
Examples: Ectopic atrial tachycardia or multifocal tachycardia
in patients with chronic lung disease OR ventricular ectopy
after MI
7. Triggered Automaticity
• Triggered activity is like a domino effect where the arrhythmia is due to the
preceding beat.
• It is initiated by Early after-depolarizations arise during the plateau phase or
the repolarization phase of the last beat
(EAD of the phase 3,LAD of phase 4 of action potential.)
• Attributed to an increase in intracellular calcium accumulation.
• It is due to the increased catecholamines or adrenergic drive.
• Subsides on removal of the stimulus or cause.
8. Re-entry
• defined as the circulation of an activation wave around an inexcitable
obstacle.
• It is the most common arrhythmia mechanism,resulting from abnormal
electrical impulse conduction.
• 2 distinct pathways that come together at beginning and end to form a loop.
• Slow conduction in the unblocked pathway.
• The fast conducting pathway is blocked because of its long refractory period so the beat
can only go down the slow conducting pathway
9. Re-entry Mechanism
• An arrhythmia is triggered by a
premature beat
• The wave of excitation from the
premature beat arrives at the distal
end of the fast conducting pathway,
which has now recovered and
therefore travels retrogradely
(backwards) up the fast pathway.
• On arriving at the top of the fast
pathway it finds the slow pathway
has recovered and therefore the
wave of excitation ‘re-enters’ the
pathway and continues in a ‘circular’
movement. This creates the re-
entry circuit
10. Re-entry Mechanism (continued)
• Sustained reentry utilizing such a
circuit, a gap (excitable gap) exists
between the activating head of
the wave and the recovering tail.
• One mechanism of termination of
reentry occurs when the
conduction and recovery
characteristics of the circuit
change and the activating head of
the wave collides with the tail,
extinguishing the tachycardia
11. Classification of Tachyarrhythmias
• Tachyarrhythmias are classified based on whether they have broad or narrow QRS
complexes on the ECG.
• Broad is defined as >0.12s (or more than 3 small squares on the standard ECG).
• Narrow is equal to or less than 0.12s.
• Broad QRS complexes are slower ventricular depolarisations that arise from the
ventricles.
• Narrow complexes are ventricular depolarisations initiated from above the
ventricles (known as supraventricular).
13. Supraventricular tachyarrhythmias
• Originate from or are dependent on conduction through the atrium or atrioventricular
(AV) node to the ventricles.
• Most produce narrow QRS-complex tachycardia (QRS duration <120 ms) characteristic
of ventricular activation over the Purkinje system.
• Conduction block in the left or right bundle branch or activation of the ventricles from
an accessory pathway produces a wide QRS complex during SVT that must be
distinguished from VT.
• SVT can be of brief duration, non-sustained, or can be sustained such that an
intervention, such as cardioversion or drug administration, is required for
termination.
15. Sinus Tachycardia
• Sinus tachycardia (>100 beats/min) is considered physiologic when it is an appropriate
response to exercise, stress, or illness.
• Sinus tachycardia can be difficult to distinguish from focal atrial tachycardia (see below)
that originates from a focus near the sinus node.
• A causative factor (such as exertion) and a gradual increase and decrease in rate favors
sinus tachycardia, whereas an abrupt onset and offset favor atrial tachycardia.
• The distinction can be difficult and occasionally requires extended ECG monitoring or even
invasive electrophysiology study.
16.
17.
18. Inappropriate sinus tachycardia
• an uncommon condition in which the sinus rate increases spontaneously at rest or out of
proportion to physiologic stress or exertion.
• Affected individuals are often women in the third or fourth decade of life.
• Fatigue, dizziness, and even syncope may accompany palpitations, which can be disabling.
• Additional symptoms of chest pain, headaches, and gastrointestinal upset are common.
• It must be distinguished from appropriate sinus tachycardia and from focal atrial
tachycardia, as discussed above.
19. Inappropriate sinus tachycardia
• Misdiagnosis of physiologic sinus tachycardia with an anxiety disorder is common. Therapy
is often ineffective or poorly tolerated.
• Careful titration of beta blockers and or calcium channel blockers may reduce symptoms.
• Clonidine and serotonin reuptake inhibitors have also been used.
• Ivabradine, a drug that causes sinus node depolarization, is promising.
• Catheter ablation of the sinus node has been used, but long-term control of symptoms is
usually poor, and it often leaves young individuals with a permanent pacemaker.
20. Focal Atrial Tachycardia
• Focal atrial tachycardia (AT) can be due to abnormal automaticity, triggered
automaticity, or a small reentry circuit confined to the atrium or atrial tissue extending
into a pulmonary vein, the coronary sinus, or vena cava. It can be sustained,
nonsustained, paroxysmal, or incessant.
• Because impulses are spread from an ectopic atrial focus, instead of the SA node, the
p waves tend to look abnormal.
• The ectopic rate can be as fast as 250bpm, but the AV node will be electrically
refractive to some of these impulses.
• Thus, the ventricular rate is often lower than the atrial rate and sometimes irregular.
21. Focal Atrial Tachycardia
• AT typically presents as an SVT either with 1:1 AV conduction or with AV block
that can be Wenckebach type conduction or fixed (e.g., 2:1 or 3:1) block.
• When 1:1 conduction to the ventricles is present, the arrhythmia can
resemble sinus tachycardia typically with a P-R interval shorter than the R-P
interval
22. Depending on the atrial rate, the P wave may fall on top of the t wave or,
during 2:1 conduction, may fall coincident with the QRS.
Maneuvers that increase AV block, such as carotid sinus massage, Valsalva
maneuver, or administration of AV nodal–blocking agents, such as
adenosine, are useful to create AV block that will expose the p wave.
Associated with significant structural heart disease such as CAD, Cor pulmonale
Rx
Digitalis, BB or CCB to slow ventricular rates
If refractory Class 1A, 1C, III drugs can be added
In digitalis toxicity the drug should be stopped and digitalis antibodies and
potassium be added.
23. Multifocal Atrial Tachycardia (MAT)
• Multifocal AT (MAT) is characterized by at least three distinct P-wave
morphologies.
• Rates are typically between 100 and 150 beats/min.
• Unlike atrial fibrillation, there are clear isoelectric intervals between P waves.
• The mechanism is likely triggered automaticity from multiple atrial foci.
• It is usually encountered in patients with chronic pulmonary disease and acute
illness.
24. MAT - Rx
• Therapy for MAT is directed at treating the underlying disease and correcting
any metabolic abnormalities.
• Electrical cardioversion has no effect.
• The calcium channel blockers verapamil or diltiazem may slow the atrial and
ventricular rate.
• Patients with severe pulmonary disease often do not tolerate beta blocker
therapy.
• MAT may respond to amiodarone, but long-term therapy with this agent is
usually avoided due to its toxicities, particularly pulmonary fibrosis.
25. Atrioventricular Nodal Re-entry Tachycardia
• AV nodal re-entry tachycardia (AVNRT) is the most common form of PSVT, representing
approximately 60% of cases referred for catheter ablation.
• It most commonly manifests in the second to fourth decades of life, often in women.
• It is often well tolerated, but rapid tachycardia, particularly in the elderly, may cause
angina, pulmonary oedema, hypotension, or syncope.
• It is not usually associated with structural heart disease.
• AVNRT occurs due the presence of a second conduction pathway in (or near) the AV
node. One pathway conducts quickly and repolarises slowly, whilst the other conducts
slowly and repolarises quickly.
26. AVNRT is triggered by an ectopic (early) atrial
beat.
The ectopic beat is forced to use the slower
conducting pathway because the fast one is still
repolarising.
The impulse reenters the AV node, in the
opposite direction, through the fast conducting
pathway which has by this time recovered.
This cycling continues as, essentially, a short
circuit loop has been established within the AV
node.
• This short circuit sends out normal ventricular depolarisations
and retrograde atrial depolarisations.
• This results in a regular, narrow complex tachycardia with a rate of 140-
240bpm.
27. ECG:
Retrograde P wave is inscribed during, slightly before, or slightly after the
QRS and can be difficult to discern.
P wave is seen at the end of the QRS complex as a “pseudo-r” in lead V1
Pseudo Q & pseudo-S waves in leads II, III, and aVF
28. Wolff-Parkinson-White (WPW) syndrome
• It is an AVRT defined as a preexcited QRS during sinus rhythm and episodes of PSVT
• Genesis involves the presence of dual conducting pathways between the atria
and the ventricles:
• The natural AV nodal His-Purkinje tract
• One or more AV accessory tract(s) (ie, AV connection or AP, Kent fibers, Mahaim fibers)
• Types of AVRT include :
Antidromic AV re-entryOrthodromic AV re-entry
29. WPW (contd..)
Presentation of AVRT
• Chest pain
• Palpitations (often sudden)
• Breathing difficulty
• Pulse that is regular and “too
rapid to count”
• Typically, a concomitant
reduction in their tolerance
for activity
Clinical features of
associated cardiac defects
may be present, such as
the following:
• Cardiomyopathy
• Ebstein anomaly
• Hypertrophic cardiomyopathy
( AMPK mutation)
30. • A shortened PR interval (typically <120 ms in a teenager or adult)
• A slurring and slow rise of the initial upstroke of the QRS complex (delta wave)
• A widened QRS complex (total duration >0.12 seconds)
• ST segment–T wave (repolarization) changes, generally directed opposite the major delta
wave and QRS complex, reflecting altered depolarization.
31. Termination of acute episodes (AVRT & AVNRT)
is done by blocking AV node conduction with the following:
• Vagal maneuvers (eg, Valsalva maneuver, carotid sinus massage, splashing cold water or ice water
on the face)
• Adults: IV adenosine 6-12 mg via a large-bore line (the drug has a very short half-life)
• Adults: IV verapamil 5-10 mg or diltiazem 10 mg
Atrial flutter/fibrillation or wide-complex tachycardia is treated as follows:
• IV procainamide or amiodarone if wide-complex tachycardia is present, ventricular tachycardia
(VT) cannot be excluded, and the patient is stable hemodynamically
The initial treatment of choice for hemodynamically unstable tachycardia is direct-
current synchronized electrical cardioversion, biphasic, as follows:
• A level of 100 J (monophasic or lower biphasic) initially
• If necessary, a second shock with higher energy (200 J or 360 J)
32. Radiofrequency ablation
• Radiofrequency ablation is indicated in the following patients:
• Patients with symptomatic AVRT
• Patients with AF or other atrial tachyarrhythmias that have rapid ventricular response via an
accessory pathway (preexcited AF)
• Patients with AVRT or AF with rapid ventricular rates found incidentally during EPS for
unrelated dysrhythmia, if the shortest preexcited RR interval during AF is less than 250 ms
• Asymptomatic patients with ventricular preexcitation whose livelihood, profession, insurability,
or mental well-being may be influenced by unpredictable tachyarrhythmias or in whom such
tachyarrhythmias would endanger the public safety
• Patients with WPW and a family history of sudden cardiac death
33. Atrial Flutter - Macroreentrant Atrial Tachycardia
• Atrial flutter is a type of supraventricular tachycardia caused by a re-entry circuit within
the right atrium.
• The length of the re-entry circuit corresponds to the size of the right atrium, resulting in a
fairly predictable atrial rate of around 300 bpm (range 200-400).
• Ventricular rate is determined by the AV conduction ratio (“degree of AV block”).
• The commonest AV ratio is 2:1, resulting in a ventricular rate of ~150 bpm.
• Higher-degree AV blocks can occur — usually due to medications or underlying heart
disease — resulting in lower rates of ventricular conduction, e.g. 3:1 or 4:1 block.
34. Atrial Flutter - Macroreentrant Atrial Tachycardia
• Atrial flutter with 1:1 conduction can occur due to sympathetic stimulation or in the
presence of an accessory pathway — especially if AV-nodal blocking agents are
administered to a patient with WPW.
• Atrial flutter with 1:1 conduction is associated with severe haemodynamic instability and
progression to ventricular fibrillation.
35. Atrial Flutter – Classification
Atypical Atrial Flutter (Common, or Type I Atrial Flutter)
• Involves the IVC & tricuspid isthmus in the reentry
circuit. Can be further classified based on the direction of
the circuit:
• Anticlockwise Reentry. This is the commonest form of
atrial flutter (90% of cases). Retrograde atrial conduction
produces:
• Inverted flutter waves in leads II,III, aVF
• Positive flutter waves in V1 – may resemble upright P waves
• Clockwise Reentry. This uncommon variant produces the
opposite pattern:
• Positive flutter waves in leads II, III, aVF
• Broad, inverted flutter waves in V1
36. Atrial Flutter – Classification
Atypical Atrial flutter (Uncommon, or Type II Atrial Flutter)
• Does not fulfil criteria for typical atrial flutter.
• Often associated with higher atrial rates and rhythm instability.
• Less amenable to treatment with ablation.
General Features
• Narrow complex tachycardia
• Regular atrial activity at ~300 bpm
• Flutter waves (“saw-tooth” pattern) best seen in leads II, III, aVF — may be
more easily spotted by turning the ECG upside down!
• Flutter waves in V1 may resemble P waves
• Loss of the isoelectric baseline
37. Atrial Flutter with 2:1 Block (anticlockwise flutter)
•inverted flutter waves in II, III + aVF at a rate of 300 bpm (one per big square)
•upright flutter waves in V1 simulating P waves
•2:1 AV block resulting in a ventricular rate of 150 bpm
•Note the occasional irregularity, with a 3:1 cycle seen in V1-3
38. Management of Atrial Flutter
• Electrical cardioversion is warranted for hemodynamic instability or severe
symptoms.
• Otherwise, rate control can be achieved with administration of AV nodal–
blocking agents, but this is often more difficult than for atrial fibrillation.
• The risk of thromboembolic events is felt to be similar to that associated
with atrial fibrillation.
39. • Anticoagulation is warranted prior to conversion for episodes more than 48 h
in duration and chronically for patients at increased risk of thromboembolic
stroke based on the CHA2DS2-VASc scoring system
40. Management of Atrial Flutter
• For a first episode of atrial flutter, conversion to sinus rhythm with no
antiarrhythmic drug therapy is reasonable.
• For recurrent episodes, antiarrhythmic drug therapy with sotalol, dofetilide,
disopyramide, and amiodarone may be considered, but more than 70% of
patients experience recurrences.
• For recurrent episodes of common atrial flutter, catheter ablation of the
cavotricuspid isthmus abolishes the arrhythmia in over 90% of patients with a
low risk of complications that are largely related to vascular access and
infrequent heart block.
• Approximately 50% of patients presenting with atrial flutter develop atrial
fibrillation within the next 5 years
41. ATRIAL FIBRILLATION
• Atrial fibrillation (AF) is characterized by disorganized, rapid, and irregular atrial activation
with loss of atrial contraction and with an irregular ventricular rate that is determined by
AV nodal conduction.
• Atrial Fibrillation (AF) is the most common sustained arrhythmia.
• Lifetime risk over the age of 40 years is ~25%.
• Clinical consequences are related to rapid ventricular rates, loss of atrial contribution to
ventricular filling, and predisposition to thrombus formation in the left atrial appendage
with potential embolization.
• Complications of AF include haemodynamic instability, cardiomyopathy, cardiac failure,
and embolic events such as stroke.
42. Classification of Atrial Fibrillation
• First episode – initial detection of AF regardless of symptoms or duration
• Recurrent AF – More than 2 episodes of AF
• Paroxysmal AF – (Triggered by Ectopic Foci) Self terminating episode < 7 days (
• Persistent AF – (Triggered by electrophysiologic remodelling fibrosis)
Not self terminating, duration > 7 days
• Long-standing persistent AF – (triggered by chronic Substrate fibrosis), > 1 year
• Permanent (Accepted) AF – Duration > 1 yr in which rhythm control interventions
are not pursued or are unsuccessful
43. Features of AF
• Ashman’s Phenomenon – presences of aberrantly conducted beats, usually of RBBB
morphology, due a long refractory period as determined by the preceding R-R
interval.
• The ventricular response and thus ventricular rate in AF is dependent on several
factors including vagal tone, other pacemaker foci, AV node function, refractory
period, and medications.
• Commonly AF is associated with a ventricular rate ~ 110 – 160.
• AF is often described as having ‘rapid ventricular response’ once the ventricular rate
is > 100 bpm.
• ‘Slow’ AF is a term often used to describe AF with a ventricular rate < 60 bpm.
• Causes of ‘slow’ AF include hypothermia, digoxin toxicity, medications, and sinus
node dysfunction.
44. Mechanism of AF
The mechanisms underlying AF are not fully understood but it requires an initiating
event (focal atrial activity / PACs) and substrate for maintenance (i.e. dilated left atrium).
• Focal activation – In which AF originates from an area of focal activity. This activity may be
triggered, due to increased automaticity, or from micro re-entry. Often located in the
pulmonary veins.
• Multiple wavelet mechanism – In which multiple small wandering wavelets are formed.
The fibrillation is maintained by re-entry circuits formed by some of the wavelets. This
process is potentiated in the presence of a dilated LA — the larger surface area facilitates
continuous waveform propagation.
45. ECG Features of Atrial Fibrillation
• Irregularly irregular rhythm.
• No P waves.
• Absence of an isoelectric baseline.
• Variable ventricular rate.
• QRS complexes usually < 120 ms unless pre-existing bundle branch block, accessory
pathway, or rate related aberrant conduction.
• Fibrillatory waves may be present and can be either fine (amplitude < 0.5mm) or
coarse (amplitude >0.5mm).
• Fibrillatory waves may mimic P waves leading to misdiagnosis.
46.
47. Management of AF
• The cornerstones of AF management are rate control and anticoagulation, as
well as rhythm control for those symptomatically limited by AF.
• New-onset AF that produces severe hypotension, pulmonary edema, or angina
should be electrically cardioverted starting with a QRS synchronous shock of
200J, ideally after sedation or anesthesia is achieved.
• If AF terminates and reinitiates, administration of an antiarrhythmic drug, such
as ibutilide, and repeat cardioversion may be considered.
• If the patient is stable, immediate management involves rate control to
alleviate or prevent symptoms & anticoagulation if appropriate.
48. AF - Cardioversion
• Cardioversion (both electrical and pharmacological) doesn't come without significant
risks, and should be undertaken cautiously in stable patients.
• Given that most AF is paroxysmal and 2/3rds of those self-terminate within 24 hours, it is
prudent to wait and see (in stable patients) if it resolves on its own initially.
• In cases that persist, cardioversion can, for some, permanently restore sinus rhythm.
• It is useful to know the exact time of onset because many methods of pharmacological
cardioversion have only shown to be beneficial within 48 hours of onset.
• Pharmacological options include Flecainide and Amiodarone.
• There is a lower rate of successful cardioversion compared with electrical cardioversion,
but it may be preferable because patients don't require conscious sedation or
anaesthesia.
49. AF - Cardioversion
• Electrical cardioversion can be attempted up to 12 months after
onset.
• Cardioversion requires prior anticoagulation as the procedure
increases the risk of thromboembolism.
• The longer the atria have been fibrillating the greater the risk of
thromboembolism, hence:
• 4 weeks of oral anticoagulation (INR >2.0) required in those presenting >48
hours of onset(or uncertain timing). or,
• Stat dose of heparin required in those presenting <48 hours since onset.
• All patients must remain anticoagulated for 4 weeks following cardioversion
therapy.
50. AF - Longterm Management
• Long-term, AF can be managed using rate or rhythm control drugs, or a combination of
both.
• The more recent the onset of AF, the more likely rhythm control will be considered.
Rate Control
• Beta-Blockers and rate limiting calcium channel blockers (Verapamil and Diltiazem) are first
line choices to lower the ventricular rate in AF.
• These are used first line in those with permanent AF, those over 65, those with ischaemic
heart disease and those who can't tolerate antiarrhythmic drugs.
• They are used with caution in congestive heart failure, as they can make it worse.
• Digoxin is preferable in this situation, due to it's concomitant inotropic action on the heart.
51. AF - Longterm Management
Rhythm Control
• Drug therapy can be instituted once sinus rhythm has been established or in anticipation of
cardioversion.
• β-Adrenergic blockers and calcium channel blockers help control ventricular rate, improve
symptoms, and possess a low-risk profile, but have low efficacy for preventing AF episodes.
• Class I sodium channel–blocking agents (e.g., flecainide, propafenone, disopyramide) are options
for subjects without significant structural heart disease, but they have negative inotropic and
proarrhythmic effects that warrant avoidance in patients with coronary artery disease or heart
failure.
• The class III agents sotalol and dofetilide can be administered to patients with coronary artery
disease or structural heart disease but have approximately a 3% risk of inducing excessive QT
prolongation and torsades des pointes.
52. AF - Longterm Management
Rhythm Control
• Dofetilide should be initiated only in a hospital with ECG monitoring, and many
physicians take this approach with sotalol as well.
• Dronedarone increases mortality in patients with heart failure.
• All of these agents have modest efficacy in patients with paroxysmal AF, of whom
approximately 30–50% will benefit.
• Amiodarone is more effective, maintaining sinus rhythm in approximately two-thirds of
patients. It can be administered to patients with heart failure and coronary artery
disease.
53. CATHETER AND SURGICAL ABLATION FOR
ATRIAL FIBRILLATION
• For patients with previously untreated but recurrent
paroxysmal AF, catheter ablation has similar efficacy to
antiarrhythmic drug therapy and is superior to
antiarrhythmic drugs for patients who have recurrent
AF despite drug treatment.
• The procedure involves cardiac catheterization,
transatrial septal puncture, and radiofrequency ablation
or cryoablation to electrically isolate the regions around
the pulmonary veins, abolishing the effect of triggering
foci to interact with the left atrial AF substrate.
• A permanent pacemaker may be indicated for those
who undergo ablation, but have significant left
ventricular dysfunction. Pacemakers also have some
benefit in terminating paroxysmal AF.
54. Ventricular Tachycardia
• Most common cause of wide complex tachycardia.(80%)
• VT arises distal to bifurcation of His bundle or vent muscle or both.
• Mechanism of impulse formation
1. Triggerd activity
2. Enhanced automaticity
3. Conduction – Reentry
Clinical Presentation
• Haemodynamically stable.
• Haemodynamically unstable — e.g hypotension, chest pain, cardiac failure, decreased
conscious level.
• Prognosis depends on any structural heart diseases
55. Classification of VT
Based on Morphology
1. Monomorphic VT
2. Polymorphic VT
3. Torsades De Pointes (Polymorphic
with QT prolongation)
4. Right Ventricular Outflow Tract
Tachycardia
5. Fascicular Tachycardia
6. Bidirectional VT
7. Ventricular Flutter
8. Ventricular Fibrillation
Based on Duration
• Sustained = Duration > 30
seconds or requiring intervention
due to hemodynamic
compromise.
• Non-sustained = Three or more
consecutive ventricular
complexes terminating
spontaneously in < 30 seconds.
56. Features suggestive of VT
• Very broad complexes (>160ms).
• Absence of typical RBBB or LBBB morphology.
• Extreme axis deviation (“northwest axis”) — QRS is
positive in aVR and negative in I + aVF.
• AV dissociation (P and QRS complexes at different
rates).
• Capture beats — occur when the sinoatrial node
transiently ‘captures’ the ventricles, in the midst of
AV dissociation, to produce a QRS complex of normal
duration.
• Fusion beats — occur when a sinus and ventricular
beat coincide to produce a hybrid complex of
intermediate morphology.
57. Features suggestive of VT
• Positive or negative concordance throughout
the chest leads, i.e. leads V1-6 show entirely
positive (R) or entirely negative (QS)
complexes, with no RS complexes seen.
• Brugada’s sign – The distance from the onset
of the QRS complex to lowest point of the S-
wave is > 100ms.
• Josephson’s sign – Notching near the lowest
point of the S-wave.
• RSR’ complexes with a taller “left rabbit
ear”. This is the most specific finding in
favour of VT. This is in contrast to RBBB,
where the right rabbit ear is taller. Brugada’s sign (red callipers) and Josephson’s sign (blue arrow)
58. Ventricular Tachycardia
Clinical Significance:
• Ventricular tachycardia may impair cardiac output with consequent hypotension,
collapse, and acute cardiac failure. This is due to extreme heart rates and lack of
coordinated atrial contraction (loss of “atrial kick”).
• The presence of pre-existing poor ventricular function is strongly associated with
cardiovascular compromise.
• Decreased cardiac output may result in decreased myocardial perfusion with
degeneration to VF.
• Prompt recognition and initiation of treatment (e.g. electrical cardioversion) is required
in all cases of VT.
59. Ventricular Tachycardia
Clinical Features Suggestive of VT
• Age > 35 (positive predictive value of 85%)
• Structural heart disease
• Ischaemic heart disease
• Previous MI
• Congestive heart failure
• Cardiomyopathy
• Family history of sudden cardiac death (suggesting conditions such as HOCM,
congenital long QT syndrome, Brugada syndrome or arrhythmogenic right
ventricular dysplasia that are associated with episodes of VT)
60. Differential Diagnosis of Wide-Complex
Tachycardia
Several arrhythmias can present as a wide-complex tachycardia (QRS > 120 ms)
including:
• Ventricular Tachycardia
• SVT with aberrant conduction due to bundle branch block
• SVT with aberrant conduction due to the Wolff-Parkinson-White syndrome
• Pace-maker mediated tachycardia
• Metabolic derangements e.g. hyperkalaemia
• Poisoning with sodium-channel blocking agents (e.g. tricyclic antidepressants)
61. Premature ventricular beats
• also referred to as premature ventricular contractions [PVCs]are single ventricular beats
that fall earlier than the next anticipated supraventricular beat.
• PVCs that originate from the same focus will have the same QRS morphology and are
referred to as unifocal.
• PVCs that originate from different ventricular sites have different QRS morphologies and
are referred to as multifocal.
• Two consecutive ventricular beats are ventricular couplets.
62. Monomorphic Ventricular Tachycardia (VT)
• Monomorphic VT has the same QRS complex from
beat to beat, indicating that the activation sequence
is the same from beat to beat and that each beat
likely originates from the same source.
• The initial site of ventricular activation largely
determines the sequence of ventricular activation.
Therefore, the QRS morphology of PVCs and
monomorphic VT provides an indication of the site of
origin within the ventricles.
• VT arises due to mini electrical circuits around edges
of infarcted myocardium. VT may arise as an escape
rhythm due to bradycardia.
63. Monomorphic Ventricular Tachycardia (VT)
• Arrhythmias that originate from the right ventricle or septum result in late activation of
much of the left ventricle, thereby producing a prominent S wave in V1 referred to as a
left bundle branch block–like configuration.
• Arrhythmias that originate from the free wall of the left ventricle have a prominent
positive deflection in V1, thereby producing a right bundle branch block–like morphology
in V1.
64. Monomorphic Ventricular Tachycardia (VT)
• An axis that is directed inferiorly, as indicated by dominant R waves in leads II, III, and
AVF, suggests initial activation of the cranial portion of the ventricle, whereas a frontal
plane axis that is directed superiorly (dominant S waves in II, III, and AVF) suggests
initial activation at the inferior wall.
65. Polymorphic VT
• Polymorphic ventricular tachycardia (PVT) is a form of ventricular tachycardia in which
there are multiple ventricular foci with the resultant QRS complexes varying in amplitude,
axis and duration. The commonest cause of PVT is myocardial ischaemia.
• Torsades de pointes (TdP) is a specific form of polymorphic ventricular tachycardia
occurring in the context of QT prolongation; it has a characteristic morphology in which the
QRS complexes “twist” around the isoelectric line.
• For TdP to be diagnosed, the patient has to have evidence of both PVT and QT
prolongation.
• Bidirectional VT is another type of polymorphic VT, most commonly associated with digoxin
toxicity.
66. Pathophysiology of PVT (Tdp)
• A prolonged QT reflects prolonged myocyte repolarisation due to ion channel malfunction.
• This prolonged repolarisation period also gives rise to early after-depolarisations (EADs).
• EADs may manifest on the ECG as tall U waves; if these reach threshold amplitude they may
manifest as premature ventricular contractions (PVCs).
• TdP is initiated when a PVC occurs during the preceeding T wave, known as ‘R on T’
phenomenon.
• The onset of TdP is often preceded by a sequence of short-long-short R-R intervals, so
called “pause dependent” TDP, with longer pauses associated with faster runs of TdP.
67. Polymorphic VT – ECG Features
• During short runs of TdP or single lead recording the characteristic “twisting” morphology
may not be apparent.
• Bigeminy in a patient with a known long QT syndrome may herald imminent TdP.
• TdP with heart rates > 220 beats/min are of longer duration and more likely to degenerate
into VF.
• Presence of abnormal (“giant”) T-U waves may precede TdP
68.
69. Ventricular Fibrillation
• Ventricular fibrillation (VF) is the the most important shockable cardiac arrest
rhythm.
• The ventricles suddenly attempt to contract at rates of up to 500 bpm.
• This rapid and irregular electrical activity renders the ventricles unable to
contract in a synchronised manner, resulting in immediate loss of cardiac output.
• The heart is no longer an effective pump and is reduced to a quivering mess.
• Unless advanced life support is rapidly instituted, this rhythm is invariably fatal.
• Prolonged ventricular fibrillation results in decreasing waveform amplitude, from
initial coarse VF to fine VF and ultimately degenerating into asystole due to
progressive depletion of myocardial energy stores.
70. Ventricular Fibrillation
• Ventricular fibrillation (VF) is the the most important shockable cardiac arrest
rhythm.
• A chaotic broad complex tachycardia which often occurs as a result of ischaemia and is
immediately life threatening.
• The ventricles suddenly attempt to contract at rates of up to 500 bpm.
• This rapid and irregular electrical activity renders the ventricles unable to
contract in a synchronised manner, resulting in immediate loss of cardiac output.
• The heart is no longer an effective pump and is reduced to a quivering mess.
71. Ventricular Fibrillation
• A chaotic broad complex tachycardia which often occurs as a result of ischaemia and is
immediately life threatening.
• VF is characterized by disordered electrical ventricular activation without identifiable QRS
complexes.
72. VF Management
• Treatment follows ACLS guidelines with
defibrillation to restore sinus rhythm.
• If resuscitation is successful, further evaluation
is performed to identify and treat underlying
heart disease and potential causes of the
arrhythmia, including the possibility that
monomorphic or polymorphic VT could have
initiated VF.
• If a transient reversible cause such as acute MI
is not identified, therapy to reduce the risk of
sudden death with an ICD is often warranted.
Chronic amiodarone therapy may be considered
for individuals who are not ICD candidates.
73. Incessant VT and Electrical Storm
• VT is incessant when it continues to recur shortly after electrical, pharmacologic,
or spontaneous conversion to sinus rhythm.
• “VT storm” or “electrical storm” refers to three or more separate episodes of VT
within 24 h, most commonly encountered in patients with ICDs.
• Slow incessant VT is sometimes asymptomatic, but can cause heart failure or
tachycardia-induced cardiomyopathy.
• Measures to reduce sympathetic tone, including β-adrenergic blockade,
sedation, and general anesthesia, have been used effectively.
• Intravenous administration of amiodarone and lidocaine can be effective for
suppression. Urgent catheter ablation can be lifesaving.
74. Ventricular arrhythmias associated with
Heart Disease
I. Idiopathic VT without structural heart
disease
A. Outflow tract origin
1. RV outflow tract: left bundle branch block
pattern with inferior axis (tall QRS in inferior
leads) and late transition in the precordial
leads
2. LV outflow tract: prominent R in V1 with
inferior axis
B. Left posterior fascicular VT
1. Right bundle branch block pattern with left
axis deviation
II. Ischemic cardiomyopathy
A. Monomorphic VT is common with prior
large myocardial infarction
B. Polymorphic VT and VF should prompt
ischemia evaluation
III. Nonischemic cardiomyopathy
A. Polymorphic VT and VF more common but
fibrotic scars can cause monomorphic VT
especially with sarcoidosis and Chagas’
disease
IV. Arrhythmogenic right ventricular
cardiomyopathy
A. Monomorphic VT usually of right ventricular
origin (left bundle branch morphology)
B. Polymorphic VT and VF can occur
independently or through degeneration of
monomorphic VT
V. Repaired tetralogy of Fallot
A. Monomorphic VT of right ventricular origin
(usually left bundle branch morphology)
VI. Hypertrophic cardiomyopathy
A. Polymorphic VT or ventricular fibrillation
B. Less commonly, monomorphic VT associated
with myocardial scars
75.
76.
77. IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
• ICDs are highly effective for termination of VT and VF and also provide
bradycardia pacing.
• ICDs decrease mortality in patients at risk for sudden death due to structural
heart diseases.
• In all cases, ICDs are recommended only if there is also expectation for survival
of at least a year with acceptable functional capacity.
78. IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
• ICDs can often terminate monomorphic VT by a burst of rapid pacing faster
than the VT, known as antitachycardia pacing (ATP).
• If ATP fails or is not a programmed treatment, as is often the case for rapid VT
or VF, a shock is delivered.
• The most common ICD complication is the delivery of unnecessary therapy in
response to a rapid SVT or electrical noise due to ICD lead failure.
79. References
Harrison’s principles of Internal Medicine 19th Ed.
Washington manual of critical care 2nd Ed.
CMDT 2016
Online Sources – Medscape & Life in the Fast Lane
Editor's Notes
A variety of mapping and pacing maneuvers typically performed during invasive electrophysiologic testing can often determine the underlying mechanism of a tachyarrhythmia.
EAD –early after depolarization
LAD -Late
Sinus tachycardia (>100 beats/min) typically occurs in response to sympathetic stimulation and vagal withdrawal, whereby the rate of spontaneous depolarization of the sinus node increases and the focus of earliest activation within the node typically shifts more leftward and closer to the superior septal aspect of the crista terminalis, thus producing taller p waves in the inferior limb leads when compared to normal sinus rhythm.
Sinus tachycardia (110/min) with first-degree AV “block” (conduction delay) with PR interval = 0.28 s. The P wave is visible after the ST-T wave in V1−V3 and superimposed on the T wave in other leads. Atrial (nonsinus) tachycardias may produce a similar pattern, but the rate is usually faster.
Orthodromic - down the AV nodal His-Purkinje system and retrograde conduction up an AP
Antidromic - down the AP and retrograde conduction up the His-Purkinje system and AV node
A right atrial map of common counterclockwise flutter is shown. Colors indicate activation time, progressing from red to yellow to green, blue, and purple. The reentry path parallels the tricuspid annulus.
A right atrial map of common counterclockwise flutter is shown. Colors indicate activation time, progressing from red to yellow to green, blue, and purple. The reentry path parallels the tricuspid annulus.
Atrial flutter with 2:1 AV conduction.
typical atrial flutter waves, partly hidden in the early ST segment, seen, for example, in leads II and V1.
Typically irregular ventricular rate
Absence of discrete P waves, replaced by irregular, chaotic F waves, in the setting of irregular QRS complexes
Aberrantly conducted beats after long-short R-R cycles (ie, Ashman phenomenon)
Heart rate (typically 110-140 beats/min, rarely >160-170 beats/min)
Preexcitation
Left ventricular hypertrophy
Unifocal PVCs follow every sinus beat in a bigeminal frequency. Trace shows electrocardiogram lead 1 and arterial pressure (Art. Pr.). Sinus rhythm beats are followed by normal arterial waveform. The arterial pressure following premature beats is attenuated (arrows) and imperceptible to palpation. The pulse in this patient is registered at half the heart rate.
B. Multifocal PVCs. The two PVCs shown have different morphologies.
Amidorone action.
Mainly class III action on the outgoing K+ channels.
Class Ib action on the Na+ channels.
Non competitive alpha antagonism (class III)
x-ray in panel C shows the components of an ICD capable of biventricular pacing. ICD generator in the subcutaneous tissue of the left upper chest, pacing leads in the right atrium and the left ventricular (LV) branch of the coronary sinus (LV lead), and a pacing/defibrillating lead in the right ventricle (RV lead) are shown